Will the Rebate Bubble Burst?

Rebate Bubble analysis from Confidio Pharmacy Solutions

Clients often ask about the future of rebates, which have been used by pharmacy benefits managers, health plans and plan sponsors to partially offset the cost of prescription drugs. In the past, rebates were viewed as a desirable financial component of the PBM pricing equation. Recently, however, rebates are viewed as a necessary evil.

Rebates are retrospective discounts off the list price of drugs that PBMs negotiate directly with drug manufacturers. PBMs leverage their aggregate book of business and essentially threaten to move market share away from one manufacturer to a competitor in an effort to lower drug prices.

Recently, formulary drug exclusions embody this process and manufacturers are at risk of being totally excluded from coverage if they cannot get their product’s price low enough. In the early 2000s, rebates were less than 6% of drug spend versus 25% of drug spend today. Did drug manufacturers simply dip into their pockets by 20% accepting much lower net prices today than in years past? Of course not. Critics argue that manufacturer list price increases are in part driven by PBMs demand for larger rebates.

This is a large part of the gross to net conundrum, which is largely driving the pressure to eliminate rebates. Adam Fein, CEO of Drug Channels Institute perfectly described this as “the ever-growing pile of money between a manufacturer’s list price for a drug and the net price after rebates and other reductions.”

Data supports that between 2013-2015 net prices (prices paid by PBMs/Plan Sponsors) trended at 3-5% while gross price (price paid by members) trended at 11-15%. Further, IQVIA pegs the gross to net value at a staggering $153 billion for 2017. Bottom line, drug manufacturers are passing on huge list price increases to consumers and in turn paying rebates sometimes as high or greater than 50% of the list price to PBMs which may or may not be passed on to Plan Sponsors. Members in high deductible health plans pay the list price of a drug, however, that price has zero correlation with the true net cost of the drug after rebates (which may not even be passed on to the employer). The confluence of significant list price increases, the growth of HDHP’s and lightning bolt stories such as the 500% price increase for the EpiPen are a tremendous amount of pressure on the rebating system.

To read the full article click here or here

Articles & Announcements

Will the Rebate Bubble Burst?
Valsartan Drug Recall Notice
Pharmacy Benefits 2020: Ready to Spend Half of Your Medical Plan Budget on Rx?
Future Pharmacy Predictions for 2019
Community Health Outreach in El Salvador